Table 1 Characteristics of 28 patients
Variable | number | percent |
|---|---|---|
Gender | Â | Â |
   Male | 22 | 78.6% |
   Female | 6 | 21.4% |
Stage (AJCC, 2002) | Â | Â |
   IIB | 3 | 10.7% |
   III | 15 | 53.6% |
   IVA/B | 10 | 35.7% |
T stage | Â | Â |
   T1-T2 | 11 | 39.3% |
   T3-T4 | 17 | 60.7% |
N stage* | Â | Â |
   N0-N1 | 8 | 28.6% |
   N2-N3 | 20 | 71.4% |
Field-dose arrangement | Â | Â |
   SIB | 24 | 85.7% |
   Conventional shrinking field | 4 | 14.3% |
Pathology | Â | Â |
   WHO I & II | 4 | 14.3% |
   WHO III | 24 | 85.7% |